NICE sets cap on drugs costing more than £20mBMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j1372 (Published 17 March 2017) Cite this as: BMJ 2017;356:j1372
- Nigel Hawkes
The Association of the British Pharmaceutical Industry has accused the government of breaking its promise to speed up the introduction of cost effective drugs into the NHS.
The association said that proposals by the National Institute for Health and Care Excellence (NICE) and NHS England to refuse to pay for any new drug that will cost more than £20m (€23m; $24m) a year was a breach of a pledge made in the Conservative Party’s election manifesto in 2015.
The decision means that new drugs would not only have to meet NICE’s threshold of cost effectiveness—set at about £20 000 to £30 000 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial